Olivier Decaux

Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

Christian Pagnoux, Alexandre Karras, C. Khouatra et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre et al. · Blood · 2018 · 420 citations · Full text

Medicine, Hematology, Oncology +15

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

Cyrille Hulin, Thierry Façon, Philippe Rodon et al. · Journal of Clinical Oncology · 2009 · 381 citations

Medicine, Pharmacology, Pharmacotherapy +17

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

Olivier Decaux, Laurence Lodé, Florence Magrangeas et al. · Journal of Clinical Oncology · 2008 · 369 citations

Medicine, Bioinformatics, Oncology +17

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Philippe Moreau, Hervé Avet‐Loiseau, Thierry Façon et al. · Blood · 2011 · 302 citations

Medicine, Hematology, Oncology +17